Home > Haematology > EHA 2019 > Myeloma > Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Expert
Prof. Michel Attal, University Institute Cancer Toulouse Oncopole, France
Conference
EHA 2019
Trial
Phase 3, ICARIA-MM

Results from the randomised, phase 3 ICARIA-MM trial, presented by Prof. Michel Attal (University Institute Cancer Toulouse Oncopole, France), showed that the addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved progression-free survival (PFS) and the overall response rate in patients with relapsed or refractory multiple myeloma (RRMM) [1].

Isatuximab, an investigational anti-CD38 monoclonal antibody, was previously found to be safe and effective in the treatment of RRMM when combined with pomalidomide and dexamethasone in a phase 1b study. Based on this finding, investigators launched the phase 3 study, which enrolled 307 patients with RRMM who had received at least 2 prior lines of therapy with lenalidomide and a proteasome inhibitor. The patients were then randomised to receive isatuximab and pomalidomide/dexamethasone or pomalidomide/dexamethasone therapy....



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on